IDARUBICIN, HIGH-DOSE CYTARABINE AND ETOPOSIDE FOR REMISSION INDUCTION IN THERAPY-RELATED ACUTE MYELOID-LEUKEMIA

被引：7

作者：

PHILPOTT, N

MEHTA, J

TRELEAVEN, J

POWLES, R

机构：

[1] Department of Haematology, Leukaemia Unit

[2] The Royal Marsden Hospital, Sutton, Surrey

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 15卷 / 1-2期

关键词：

CYTARABINE; ETOPOSIDE; IDARUBICIN; SECONDARY ACUTE MYELOID LEUKEMIA; THERAPY-RELATED ACUTE MYELOID LEUKEMIA;

D O I：

10.3109/10428199409051686

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Five patients with therapy-related acute myeloid leukemia received combination induction chemotherapy with idarubicin, high-dose cytarabine, and etoposide. Complete remission was achieved in all patients with a single course of therapy. Treatment-related toxicity included nausea, vomiting, mucositis, diarrhea, and liver and kidney function abnormalities, and was low in all patients. There were no deaths during induction therapy. We conclude that this combination is well-tolerated in induction of remission in secondary acute myeloid leukemia, and warrants further assessment because of a very good complete remission rate.

引用

页码：127 / 130

页数：4

共 50 条

[21] INDUCTION THERAPY WITH HIGH-DOSE CYTARABINE AND ANTHRACYCLINES IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
Gil, Perez Angela
Vazquez, Ramo Alejandro
De Rojas, de Pablo Teresa
Torralba, Gomez de Suso Miguel
Nuevo, Lopez Irene
Subira, Perez Dolores
Merchan, Munoz Beatriz
Perez, Ortega Alba
De Miguel, Llorente Dunia
HAEMATOLOGICA, 2020, 105 : 384 - 385
[22] Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine
Wiedower, Eric
Jamy, Omer
Martin, Michael G.
ANTICANCER RESEARCH, 2015, 35 (11) : 6287 - 6290
[23] Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study
Yue-ying Mao
Hua-cong Cai
Kai-ni Shen
Chang, Long
Zhang, Lu
Zhang, Yan
Feng, Jun
Wang, Wei
Yang, Chen
Tie-nan Zhu
Ming-hui Duan
Dao-bin Zhou
Xin-xin Cao
Li, Jian
ANNALS OF HEMATOLOGY, 2022, 101 (04) : 831 - 836
[24] Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study
Yue-ying Mao
Hua-cong Cai
Kai-ni Shen
Long Chang
Lu Zhang
Yan Zhang
Jun Feng
Wei Wang
Chen Yang
Tie-nan Zhu
Ming-hui Duan
Dao-bin Zhou
Xin-xin Cao
Jian Li
Annals of Hematology, 2022, 101 : 831 - 836
[25] Etoposide and mitoxantrone in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy with cytarabine and idarubicin
McHayleh, W. M.
Redner, R.
Sehgal, R.
Raptis, A.
Agha, M.
Natale, J.
Luong, T.
Schlesselman, J. J.
Foon, K.
Boyiadzis, M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[26] Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia
Lee, Mark Hong
Kim, Sung-Yong
LEUKEMIA & LYMPHOMA, 2016, 57 (10) : 2268 - 2274
[27] A Phase I Study of Idarubicin Dose Escalation for Remission Induction Therapy in Acute Myeloid Leukemia
Lee, Mark
Kim, Sung-Yong
BLOOD, 2015, 126 (23)
[28] MAINTENANCE WITH LOW-DOSE CYTARABINE FOR ACUTE MYELOID-LEUKEMIA IN COMPLETE REMISSION
ARCHIMBAUD, E
ANGLARET, B
THOMAS, X
JAUBERT, J
SEBBAN, C
GUYOTAT, D
FIERE, D
ANNALS OF HEMATOLOGY, 1992, 65 (02) : 71 - 74
[29] CYTARABINE PLUS IDARUBICIN OR DAUNORUBICIN AS INDUCTION AND CONSOLIDATION THERAPY FOR PREVIOUSLY UNTREATED ADULT PATIENTS WITH ACUTE MYELOID-LEUKEMIA
WIERNIK, PH
BANKS, PLC
CASE, DC
ARLIN, ZA
PERIMAN, PO
TODD, MB
RITCH, PS
ENCK, RE
WEITBERG, AB
BLOOD, 1992, 79 (02) : 313 - 319
[30] IDARUBICIN FOR REMISSION INDUCTION OF ACUTE MYELOID-LEUKEMIA - UNITED-KINGDOM MULTICENTER EXPERIENCE
RASSAM, SMB
TURKER, A
POWLES, RL
SMITH, AG
NEWLAND, AC
ERSKINE, JG
PEARCE, RM
GOLDSTONE, AH
SEMINARS IN ONCOLOGY, 1993, 20 (06) : 13 - 19

← 1 2 3 4 5 →